Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | MMP15 | P51511 | 1/20 | 0.41 |
| ▸ | MMP16 | P51512 | 1/20 | 0.41 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19148290 | 0.86 | ADRA1D (0.44) | ADRA1DADRA1AADRA1BLMNAMAPT | |
| SCHEMBL19173184 | 0.75 | HTT (0.42) | ADRA1DADRA1AADRA1BLMNAALDH1A1 | |
| SCHEMBL19149405 | 0.71 | HTT (0.43) | LMNAMAPTHTTSMN1; SMN2TDP1 | |
| SCHEMBL23489367 | 0.71 | ALDH1A1 (0.45) | ADRA1DADRA1AADRA1BALDH1A1KMT2A | |
| Benzylamine SCHEMBL5820436 | 0.68 | BCHE (0.54) | LMNAALDH1A1KDM4ERECQLKMT2A | |
| SCHEMBL4611094 | 0.68 | ALDH1A1 (0.48) | LMNAALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL9117898 | 0.68 | LMNA (0.48) | LMNAALDH1A1KDM4EHPGDRECQL | |
| SCHEMBL1363911 | 0.68 | LMNA (0.64) | LMNAALDH1A1KMT2AMAPTCYP1A2 | |
| SCHEMBL10528237 | 0.68 | CYP2C19 (0.53) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL19149070 | 0.67 | L3MBTL1 (0.38) | LMNAALDH1A1KMT2AMEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599584-B2 | Indoline derivatives, compositions comprising them and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2026-04-14 | — | — | US | disclosed |
| EP-3405454-B1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2021-12-29 | — | — | EP | disclosed |
| US-20210169850-A1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-06-10 | — | — | US | disclosed |
| EP-3405454-A1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017125932-A1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169850-A1 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | IDO1, IDO2, INMT | ADRA1D 726/4885ADRA1A 548/4885ADRA1B 630/4885 |
| US-12599584-B2 | Indoline derivatives, compositions comprising them and uses thereof | IL6, TNF, IDO1 | ADRA1D 493/4885ADRA1A 752/4885ADRA1B 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.